Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

May 05, 2009; 72 (18) Articles

Bevacizumab and irinotecan for recurrent oligodendroglial tumors

S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, C. Dehais, M. Sierra del Rio, Y. Meng, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, J. Y. Delattre
First published May 4, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181a413be
S. Taillibert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. A. Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Granger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Marie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Carpentier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Guillevin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Bellanger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Mokhtari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Rousseau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Psimaras
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Dehais
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Sierra del Rio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Meng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Laigle-Donadey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Hoang-Xuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Sanson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Y. Delattre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, C. Dehais, M. Sierra del Rio, Y. Meng, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, J. Y. Delattre
Neurology May 2009, 72 (18) 1601-1606; DOI: 10.1212/WNL.0b013e3181a413be

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
440

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Background: Treatment with a regimen of bevacizumab–irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied.

Methods: The bevacizumab–irinotecan regimen was retrospectively evaluated in a consecutive series of 25 patients with recurrent oligodendroglial tumors. All patients had not responded to previous treatment with radiation therapy and at least one line of temozolomide chemotherapy. Bevacizumab (10 mg/kg) and irinotecan (125 or 340 mg/m2 according to the antiepileptic regimen) were administered every 14 days. Response was measured clinically and on monthly MRI.

Results: The objective response rate was 72% (20% complete response, 52% partial response). After a median follow up of 202 days, the median progression-free survival was 140 days (95% confidence interval [CI] 116–∞), and overall survival had not been reached. The 6-month progression-free survival was 42% (95% CI 26%–67%). Among the 17 patients in whom the status of the main molecular alterations of gliomas could be evaluated (search for deletions of chromosomes 1p, 19q, 9p, and 10q and amplification of epidermal growth factor receptor, mouse double-minute gene, and cyclin-dependent kinase 4 gene), no relation could be found between the response rate and the type of genetic change (including 1p-19q codeletion). The profile of tolerance was fair, with treatment discontinuation in 20% of patients. Intratumoral hemorrhages occurred in 6 patients (24%), but the treatment had to be discontinued because of symptomatic bleeding in only 1 patient (4%).

Conclusions: This regimen is effective in recurrent oligodendrogliomas, and the overall tolerance is acceptable.

Glossary

CCNU=
lomustine;
CDK4=
cyclin-dependent kinase 4 gene;
CI=
confidence interval;
DVT=
deep venous thrombosis;
EGFR=
epidermal growth factor receptor;
EIAED=
enzyme-inducing antiepileptic drug;
FLAIR=
fluid-attenuated inversion recovery;
G-CSF=
granulocyte colony-stimulating factor;
KPS=
Karnofsky performance status;
MDM2=
mouse double-minute gene;
PFS=
progression-free survival;
RT=
radiation therapy;
TMZ=
temozolomide.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

  • Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    • Marc C. Chamberlain, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, SCCA, 825 Eastlake Ave East, PO Box 19023, MS G4940, Seattle, WA 98109chambemc@u.washington.edu
    Submitted July 31, 2009
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Primary brain tumor
  • Clinical trials Observational study (Cohort, Case control)
  • Chemotherapy-tumor

Alert Me

  • Alert me when eletters are published
Neurology: 100 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise